![](/img/cover-not-exists.png)
Rituximab is not associated with increased risk of second primary malignancies in Israeli patients with diffuse large B cell lymphoma treated with RCHOP regimen
Neeman, Yuval, Perry, Chava, Silverman, Barbara, Waintraub, Nizan, Avivi, IritJournal:
Leukemia & Lymphoma
DOI:
10.1080/10428194.2020.1779257
Date:
July, 2020
File:
PDF, 1.09 MB
2020